Combined urolithin A and STING inhibitor C176 synergistically reduces liver injury, inflammation, and fibrosis in a mouse steatohepatitis model

The Finding

A recent study by Hamad et al. from the Biological Sciences Department investigated a dual-node strategy to combat steatohepatitis (SH), a condition characterized by metabolic stress and mitochondrial damage. Using a high-fat diet plus streptozotocin mouse model, the researchers found that combining urolithin A (UA) with the murine STING inhibitor C176 produced superior, multi-domain control over disease biology compared to either agent alone. The combination therapy demonstrated predominant synergistic activity (ΔBliss and ΔHSA > 0 for most endpoints), frequently restoring markers to levels seen in healthy control animals. This coordinated approach significantly reduced hepatic ALT/AST levels, lowered serum and hepatic triglycerides and cholesterol, suppressed the cGAS-STING pathway, restored mitophagy, and decreased fibrosis markers.

How They Got There

The investigation employed a controlled study design where male C57BL/6 J mice, induced with steatohepatitis, were divided into groups receiving urolithin A, C176, or their combination. A steatohepatitis-only group served as the primary comparison, alongside a healthy control group. While the abstract did not specify the exact sample size for each group, the findings were derived from this murine cohort.

The researchers assessed a broad range of outcome variables across multiple biological domains:

Liver Injury Markers: Alanine transaminase (ALT) and aspartate transaminase (AST) levels.

Lipid Metabolism: Serum and hepatic triglycerides, and cholesterol levels.

Glycemic Control: Fasting glucose, insulin, and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR).

cGAS-STING/Type-I Interferon Signaling: Expression of *Ifnb1*, *Cxcl10*, IFN-β, CXCL10, and phosphorylation of STING (p-STING), TBK1 (p-TBK1), and IRF3 (p-IRF3).

Mitochondrial Damage: Levels of cytosolic mitochondrial DNA (mtDNA) and mitochondrial transcription factor A (mtTFA).

Autophagy/Mitophagy Markers: Ratios of LC3-II/I, cleaved-PINK1, phosphorylated PARKIN (p-PARKIN), and p62.

Inflammasome/Cytokines: NLRP3, IL-1β, and TNF-α.

Fibrosis Indicators: Hydroxyproline content, *Col1a1* expression, and *Tgfb1*/TGF-β1 levels.

Through this comprehensive analysis, the study compared the individual and combined effects of UA and C176 on these endpoints relative to the steatohepatitis and control groups.

The Mechanism: What Happens Biologically

The study focused on the mtDNA-cGAS-STING pathway, a critical nexus linking metabolic stress, mitochondrial damage, and inflammation. Steatohepatitis leads to mitochondrial dysfunction, causing mitochondrial DNA (mtDNA) to leak into the cytoplasm. This cytosolic mtDNA then activates the cGAS-STING pathway, triggering an inflammatory cascade.

Urolithin A acts as a mitophagy enhancer, promoting the selective clearance of damaged mitochondria. This process reduces the release of mtDNA into the cytosol, thus mitigating an upstream trigger of inflammation. C176, on the other hand, functions as a murine STING inhibitor, directly blocking the adaptor protein STING downstream in the pathway. This prevents the full activation of the immune response, including the production of type-I interferons like IFN-β and CXCL10, which drive inflammation and fibrosis. The combination leverages both these actions: UA reduces the initial stress signal (cytosolic mtDNA and mtTFA), while C176 directly quells the inflammatory signaling (p-STING, p-TBK1, p-IRF3 activation). This coordinated upstream and downstream targeting explains the observed synergistic improvements in liver injury, lipid metabolism, and fibrotic markers.

Study Limitations

This research, while providing significant mechanistic insights, presents several limitations. The study was conducted in a mouse model of steatohepatitis, meaning the findings may not directly translate to human physiology or other disease contexts. The abstract also did not specify the sample size of the animal cohorts, which can be an important factor in evaluating the robustness of the results. Furthermore, the abstract does not detail the duration of the intervention, which could impact the long-term applicability or reversibility of the observed effects.

Practical Application

This study was conducted in a mouse model of steatohepatitis, a specific disease state. It's too early to apply these findings to a personal protocol for healthy adults optimizing performance. Before any human application can be considered, extensive human clinical trials would be necessary to establish safety, effective dosages, and efficacy in humans, both in disease models and healthy cohorts. Further research would also be needed to confirm the precise mechanisms and long-term effects of combining urolithin A and STING inhibitors in a human physiological context.

Disclaimer: This article is for informational and educational purposes only. The information presented does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before modifying your diet, supplementation, or exercise routines. The scientific studies cited reflect the state of knowledge at their publication date and may be subject to revision.